Lyon, France
Joined February 2012
- Tweets4.6K
- Following757
- Followers372
- Likes410
Thomas Pierret 🫁 retweeted
This press release, coupled with PAPILLON and REZLIENT3, tell me that upfront platinum chemo is an important part of the treatment strategy for #Egfr Exon 20 NSCLC.
@Exon20Group @EGFRResisters @EgfrUk @EGFRSummit @OncoAlert @Lung_Cancers @YoungLungCancer
Phase III FURVENT trial of 1L firmonertinib monotherapy vs pemetrexed-based chemo does not meet primary endpoint of PFS in pts with EGFR exon 20 insertion mutant NSCLC. Press release notes OS trend and clinical benefit by RR and PFSinv. Await full data.
ir.arrivent.com/news-release…
Thomas Pierret 🫁 retweeted
Primary tracheal SCC is rare and can cause significant morbidity.
Our case report/focused review @ClinicalLung describe a durable response to #pembrolizumab. This adds to the evidence suggesting that PD-(L)1 blockade may have a role in this disease.
bit.ly/4hpDMp8
Thomas Pierret 🫁 retweeted
Big melanoma data in @NatureMedicine 👇
A pooled analysis of 1,038 patients with resectable melanoma treated before surgery. Among the 735 who received immunotherapy, 58% had little or no viable tumor left at surgery.
Those patients? ~98% alive at 5 years.
And their 5-year recurrence-free survival was similar with or without additional immunotherapy after surgery (90.8% vs 90.6%).
So if treatment already worked this well, do patients need more?
Not randomized, so prospective trials are needed. But very encouraging.
Thomas Pierret 🫁 retweeted
Excited to present our work on Tarlatamab and CNS efficacy and treatment beyond CNS progression, now in press @JTOonline!
🧠 Meaningful intracranial activity (ICR ORR 39%), N=91, including active, untreated brain mets excluded from trials.
⭐️ Treatment beyond isolated CNS progression with local therapy appears efficacious and safe: patients stayed on treatment a median of 4.3 extra months (N=9).
🛡️ Concurrent CNS radiation appears safe: no grade ≥3 ICANS events
🔗 doi.org/10.1016/j.jtocrr.202…
@DukeCancer @UNC_Lineberger @DHESS280 @DukeMets @ShetalAPatel @drshieldsmd @alissajcooper @GlopesMd @lungoncdoc @StephenVLiu @chulkimMD @Latinamd @JessieStuart316 @LungCancerEu @Lung_Cancers @OncoAlert
Thomas Pierret 🫁 retweeted
Excited to share our new @JTOonline publication on pulmonary toxicity from ADCs in lung cancer.
24 studies, 2,855 patients
🫁 Pneumonitis/ILD: 8.0%
⚠️ Grade ≥3 pulmonary AEs: 6.9%
Extremely grateful to @ChristianRolfo for his mentorship!
jto.org/article/S1556-0864(2…
@TischCancer
Thomas Pierret 🫁 retweeted
Very honored to present the results of the PERSEE phase III trial (GFPC 01-2020) in an oral session at #ESMO26 in Madrid 🇪🇸
📅 Sunday, October 25
🕙 10:15 AM
🎤 Abstract 2614O
cslide.ctimeetingtech.com/es…
Thank you to the investigators, the GFPC, Brest CHU and Centre Leon Bérard !
Thomas Pierret 🫁 retweeted
🆙 #ESMO26 Proffered Paper I: #LCSM Mets
🔥PERSEE (GFPC 01-2020): Pembrolizumab With or Without Platinum-Based Chemotherapy as First-Line Treatment in Advanced NSCLC With PD-L1 ≥50%, Phase 3 Trial
🎙️ @decroisette
🔢2614O
☑️NCT04547504
🔗 cslide.ctimeetingtech.com/es…
@OncoAlert @Larvol @myESMO @IASLC
Thomas Pierret 🫁 retweeted
#WCLC 2026 "One slide says it all"! from our presentation on impact of KRAS G12C on patient outcomes in EMPOWER lung 01 phase 3 trial of 1st line cemiplimab vs platinum chemotherapy. Explanation: G12C is highly associated with smoking, most neoantigenic, favorable to ICI.
Thomas Pierret 🫁 retweeted
🆙 #WCLC26 #LCSM Mini Oral Session
🔥 SOHO-01: Molecular Landscape of Acquired Resistance to Sevabertinib in HER2-mutant NSCLC
🎯85 pts with paired BL-PD plasma NGS
🎯Resistance-associated events in 30.1%
🎯Secondary HER2 T862A 16.4%, HER2 amplification 2.7%; C805S not detected
🎯Bypass/downstream alterations less frequent (PIK3CA/PTEN, MAPK pathway, 12.3%)
🎙️ @LeXiuning
🔢 MO12.04
☑️ NCT05099172
🔗 cattendee.abstractsonline.co…
@OncoAlert @Larvol @IASLC
🆙 #WCLC26 #LCSM Mini Oral Session
🔥 SOHO-01: Molecular Landscape of Acquired Resistance to Sevabertinib in HER2-mutant NSCLC
🎯85 pts with paired BL-PD plasma NGS
🎯Resistance-associated events in 30.1%
🎯Secondary HER2 T862A 16.4%, HER2 amplification 2.7%; C805S not detected
🎯Bypass/downstream alterations less frequent (PIK3CA/PTEN, MAPK pathway, 12.3%)
🎙️ @LeXiuning
🔢 MO12.04
☑️ NCT05099172
🔗 cattendee.abstractsonline.co…
@OncoAlert @Larvol @IASLC
Thomas Pierret 🫁 retweeted
#WCLC26 🌟First report of a combination of a #bispecific targeting PDL1 x VEGF (pumitamig) plus a B7-H3.l ( Elfie-D) #ADC in ES-SCLC, producing excellent responses in all lines of treatment and especially 1L with tolerable toxicity profile. Requires longer follow up to evaluate long-term tolerability of ADCs and the contribution of the bispecific component. Challenging to see how this combo will fit into the TCE in 1L era
Thomas Pierret 🫁 retweeted
DUMAS: Preoperative nivolumab + chemotherapy in Pancoast tumor, a rare entity with many surgical challenges, lead to impresive 58%pCR, and PFS at 24 months 75%. Eager to see more mature survival results but these results already have clinical implications @gecp_org #WCLC26 #LCSM @IASLC
Thomas Pierret 🫁 retweeted
Dr. @JuliaRotow presents DESTINYLung04, 1L T-DXd in HER2 mt NSCLC. Study met its primary endpoint of mPFS, 14.3 vs 8.3 mo, HR 0.63; P<0.0001. No OS benefit but durability and response favored T-DXd.
ILD and ♥️ AEs require awareness and close monitoring
@IASLC #WCLC26 #LCSM
Thomas Pierret 🫁 retweeted
ARROS-1: 1L Zidesamtinib in ROS1+
Ph1/2, n=94
✅ORR 94%, CR 15%
✅mPFS NR, 90% 1yr PFS
✅ icRR 100%
✅ Low Gr3+ AE
🤔
Impressive efficacy, better than Repo / Tale
But need longer F/U & Ph3
Better tolerated than most other TKIs
CNS activity ++ 👍
❓sequencing
#WCLC26
Thomas Pierret 🫁 retweeted
Destiny-Lung04!.
Many factors can influence OS. For now, it seems more reasonable to base treatment selection on toxicity profiles. From that perspective, a TKI appears to be the more appropriate first-line approach in HER2 TKD-mutant NSCLC.
#WCLC26 In DESTINY-Lung04, no OS signal yet. Toxicities led to discontinuation in 16% of both arms. Biggest concern here is the ILD at 20.8% - while most were grade 1/2 and resolved, these are still high rates. This will impact delivery and possibly subsequent therapies...
Thomas Pierret 🫁 retweeted
#WCLC26 PCI decreased the cumulative incidence of brain metastases but this did not improve PFS, it just changed the patterns of recurrence. With MRI surveillance, 18% of pts relapsed in the brain first and 31% extracranial. With PCI, 5% had CNS as initial progression and 45% had extracranial progression. But no significant difference in brain metastasis free survival. And importantly, far more treatment related adverse events with PCI including a grade 5 encephalopathy. MRI surveillance, without PCI, should be the standard going forward for pts with SCLC.
Thomas Pierret 🫁 retweeted
IASLC expert panel proposes an updated pulmonary carcinoid/NET classification ( Expected to be included into the forthcoming WHO thoracic blue book)
1. Keep “carcinoid” as the main diagnostic term for thoracic clinicians, while moving toward the “NET” nomenclature used in other organs
2. Add Ki-67 as a diagnostic criterion. 5% threshold is pulmonary specific
3. Formally recognize rare carcinoid/NET G3 tumors (higher proliferation, but molecularly closer to NETs than to high-grade NECs)
More on jto.org/article/S1556-0864%2…
Slides below from Dr. Bellizzi’s presentation: What’s New in Neuroendocrine Tumors (WHO 6th Edition, 2026)
youtube.com/live/o8IqIDiN_Jw… #pathology #pathX
Thomas Pierret 🫁 retweeted
Dr Goldman #WCLC26 presenting DeLLphi-309 interval dosing of Tarlatamab: q2 vs q3 vs q4 week. Minor imbalances of patient characteristics.
⭐️Overall similar PFS, OS, and tox. Provides promising early data to support more flexible dosing!
@IASLC @BZhangMD @SclcSMASHERS @drshieldsmd
Thomas Pierret 🫁 retweeted
🆙#WCLC26 #LCSM Oral Session
🔥NAUTIKA1: Neoadjuvant Divarasib Shows Manageable Safety and Promising Activity in Resectable KRAS G12C+ NSCLC
🎙️ @ChaftJamie
🔢OA04.04
🎯MPR 42%, pCR 16% (n=19)
🎯Radiographic ORR 55%
🎯No Treatment Discontinuations Due to AEs
☑️NCT04302025
🔗 cattendee.abstractsonline.co…
@OncoAlert @Larvol @IASLC @KRASKickers
🆙#WCLC26 #LCSM Oral Session
🔥NAUTIKA1: Neoadjuvant Divarasib Shows Manageable Safety and Promising Activity in Resectable KRAS G12C+ NSCLC
🎙️ @ChaftJamie
🔢OA04.04
🎯MPR 42%, pCR 16% (n=19)
🎯Radiographic ORR 55%
🎯No Treatment Discontinuations Due to AEs
☑️NCT04302025
🔗 cattendee.abstractsonline.co…
@OncoAlert @Larvol @IASLC @KRASKickers
Thomas Pierret 🫁 retweeted
Dr. @MartinReck2 presents MDT-Bridge at #WCLC26: pts with resectable or borderline resectable NSCLC received 1-2 cycles of durvalumab + chemotherapy then surgery if resectable or CRT if not, followed by adjuvant/consolidation durvalumab. Of those with borderline resectable NSCLC, 62% underwent resection (97% R0). Overall resection rate 75% and 27% pCR rate.
